Pfizer Maneuvers to Snare AstraZeneca as World Waits for U.S. Jobs Data

Global indices are mixed ahead of the U.S. non-farm payrolls report for April as many centers return to work after the May Day public holiday. AstraZeneca investors appear under-whelmed after the first Pfizer sweetener to an indicative offer initially proposed in early January. The Viagra maker is now offering about $106 billion for the British drugs group¿s stock and is lobbying U.K. politicians including PM Cameron furiously to win their approval.